Journal of Thrombosis and Thrombolysis

, Volume 34, Issue 1, pp 143–163 | Cite as

Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20–21, 2011, Salvador, Bahia, Brazil

  • Renato D. Lopes
  • Richard C. Becker
  • L. Kristin Newby
  • Eric D. Peterson
  • Elaine M. Hylek
  • Christopher B. Granger
  • Mark Crowther
  • Tracy Wang
  • Antonio C. Carvalho
  • Otavio Berwanger
  • Roberto R. Giraldez
  • Gilson Soares Feitosa
  • Jorge Pinto Ribeiro
  • Eduardo Darze
  • Renato A. K. Kalil
  • Marianna Andrande
  • Fabio Villas Boas
  • Jadelson Andrade
  • Ana Thereza Rocha
  • Robert A. Harrington
  • Antonio C. Lopes
  • David A. Garcia
Article

Abstract

To discuss and share knowledge about advances in the care of patients with thrombotic disorders, the Fourth International Symposium of Thrombosis and Anticoagulation was held in Salvador, Bahia, Brazil, from October 20–21, 2011. This scientific program was developed by clinicians for clinicians and was promoted by three major clinical research institutes: the Brazilian Clinical Research Institute, the Duke Clinical Research Institute of the Duke University School of Medicine, and Hospital do Coração Research Institute. Comprising 2 days of academic presentations and open discussion, the symposium had as its primary goal to educate, motivate, and inspire internists, cardiologists, hematologists, and other physicians by convening national and international visionaries, thought-leaders, and dedicated clinician-scientists. This paper summarizes the symposium proceedings.

Keywords

Thrombosis Antithrombotic therapy Guidelines Clinical research 

Recommended reading

  1. Ageno W, Garcia D et al (2009) Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment. Am J Hematol 84(9):584–588PubMedCrossRefGoogle Scholar
  2. Agnelli G, Bergqvist D et al, On Behalf of the PEGASUS investigators (2005) Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92:1212–1222Google Scholar
  3. Alexander JH, Lopes RD et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365(8):699–708PubMedCrossRefGoogle Scholar
  4. Alexander JH, Becker RC et al (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119(22):2877–2885PubMedCrossRefGoogle Scholar
  5. Alexander KP, Peterson ED (2010) Minimizing the risks of anticoagulants and platelet inhibitors. Circulation 121:1960–1970PubMedCrossRefGoogle Scholar
  6. Anderson FA Jr, Zayaruzny M et al (2007) Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 82(9):777–782PubMedCrossRefGoogle Scholar
  7. Anderson WG, Alexander SC et al (2008) ‘What concerns me is…’ Expression of emotion by advanced cancer patients during outpatient visits. Support Care Cancer 16(7):803–811PubMedCrossRefGoogle Scholar
  8. Angiolillo DJ, Gibson CM et al (2011) Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 89(1):65–74PubMedCrossRefGoogle Scholar
  9. Angiolillo DJ, Shoemaker SB et al (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115(6):708–716PubMedCrossRefGoogle Scholar
  10. Ansell J, Hirsh J et al (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):160S–198SPubMedCrossRefGoogle Scholar
  11. Antiplatelet Trialists Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy—III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 308:235–246CrossRefGoogle Scholar
  12. Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449–1457CrossRefGoogle Scholar
  13. Ay C, Dunkler D et al (2010) Prediction of venous thromboembolism in cancer patients. Blood 116(24):5377–5382PubMedCrossRefGoogle Scholar
  14. Baker WL, Cios DA et al (2009) Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 15:244–252PubMedGoogle Scholar
  15. Barbar S, Noventa F et al (2010) A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 8(11):2450–2457PubMedCrossRefGoogle Scholar
  16. Berger JS, Frye CB et al (2008) Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 52(21):1693–1701PubMedCrossRefGoogle Scholar
  17. Beyth RJ, Quinn LM et al (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105:91–99PubMedCrossRefGoogle Scholar
  18. Bhatt DL, Cryer BL et al (2010) Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363(20):1909–1917PubMedCrossRefGoogle Scholar
  19. Brandt JT, Close SL et al (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5(12):2429–2436PubMedCrossRefGoogle Scholar
  20. Breet NJ, van Werkum JW et al (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303(8):754–762PubMedCrossRefGoogle Scholar
  21. Camm AJ, Kirchhof P et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. Eur Heart J 31:2369–2429PubMedCrossRefGoogle Scholar
  22. Campo G, Parrinello G et al (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57(25):2474–2483PubMedCrossRefGoogle Scholar
  23. Caprini JA (2010) Mechanical methods for thrombosis prophylaxis. Clin Appl Thromb Hemost 16(6):668–673PubMedCrossRefGoogle Scholar
  24. Chan MY, Cohen MG et al (2008) Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 117(22):2865–2874PubMedCrossRefGoogle Scholar
  25. Cohen AT, Tapson VF et al (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371(9610):387–394PubMedCrossRefGoogle Scholar
  26. Connolly SJ, Ezekowitz MD et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151PubMedCrossRefGoogle Scholar
  27. Cook D, Meade M et al (2011) Prophylaxis for thromboembolism in critical care trial protocol and analysis plan. J Crit Care 26(223):e1–9Google Scholar
  28. Crowther MA, Warkentin TE (2009) Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost 7(Suppl 1):107–110PubMedCrossRefGoogle Scholar
  29. CURRENT-OASIS 7 Investigators (2010) Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363:930–942Google Scholar
  30. Eikelboom JW, Weitz JI (2008) Selective factor Xa inhibition for thromboprophylaxis. Lancet 372(9632):6–8PubMedCrossRefGoogle Scholar
  31. Eikelboom JW, Mehta SR et al (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114(8):774–782PubMedCrossRefGoogle Scholar
  32. Eriksson BI, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358(26):2765–2775PubMedCrossRefGoogle Scholar
  33. Eriksson BI, Dahl OE et al (2007) Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5(11):2178–2185PubMedCrossRefGoogle Scholar
  34. Fang MC, Go AS et al (2011) A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 58:395–401PubMedCrossRefGoogle Scholar
  35. Ferraris VA, Brown JR et al (2011) 2011 update to the Society of Thoracic Surgeons and Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 91:944–982PubMedCrossRefGoogle Scholar
  36. Fitchett D, Eikelboom J et al (2009) Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. Can J Cardiol 25(12):683–689PubMedCrossRefGoogle Scholar
  37. Francis CW (2007) Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med 356(14):1438–1444PubMedCrossRefGoogle Scholar
  38. Gage BF, Yan Y et al (2006) Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151:713–719PubMedCrossRefGoogle Scholar
  39. Gage BF, Waterman AD et al (2001) Validation of clinical classification schemes for predicting stroke. JAMA 285:2864–2870PubMedCrossRefGoogle Scholar
  40. Garcia D, Libby E et al (2010) The new oral anticoagulants. Blood 115(1):15–20PubMedCrossRefGoogle Scholar
  41. Geerts WH, Bergqvist D et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):381S–453SPubMedCrossRefGoogle Scholar
  42. Gharacholou SM, Alexander KP et al (2010) Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative. Am Heart J 159(5):757–763PubMedCrossRefGoogle Scholar
  43. Gibson CM, Mega JL et al (2011) Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome–thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J 161(5):815–821Google Scholar
  44. Gilard M, Arnaud B et al (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51(3):256–260PubMedCrossRefGoogle Scholar
  45. Goodman SG, Clare R et al (2012) Association of proton-pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from PLATO. Circulation Jan 18. [Epub ahead of print]Google Scholar
  46. Granger CB, Alexander JH et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992PubMedCrossRefGoogle Scholar
  47. Gurbel PA, Bliden KP et al (2009) Randomized double-blind assessment of the ONSET and OFFSET of antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120:2577–2585PubMedCrossRefGoogle Scholar
  48. Gurbel PA, Becker RC et al (2007) Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50(19):1822–1834PubMedCrossRefGoogle Scholar
  49. Hamm CW, Bassand J-P et al (2011) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J [Epub ahead of print]Google Scholar
  50. Hansen ML, Sorensen R et al (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170(16):1433–1441PubMedCrossRefGoogle Scholar
  51. Harrington RA, Becker RC et al (2008) Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):670S–707SPubMedCrossRefGoogle Scholar
  52. Heit JA (2008) The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 28(3):370–372PubMedCrossRefGoogle Scholar
  53. Held C, Åsenblad N et al (2011) Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass graft surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 57:672–684PubMedCrossRefGoogle Scholar
  54. Hillis LD, Smith PK et al (2011) 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. J Am Coll Cardiol [Published online November 7, 2011]Google Scholar
  55. Hirsh J, Guyatt G et al (2008a) Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6):110S–112SPubMedCrossRefGoogle Scholar
  56. Hirsh J, Guyatt G et al (2008b) Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):71S–109SPubMedCrossRefGoogle Scholar
  57. Hochholzer W, Trenk D et al (2010) Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55:2427–2434PubMedCrossRefGoogle Scholar
  58. Hochholzer W, Trenk D et al (2005) Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111(20):2560–2564PubMedCrossRefGoogle Scholar
  59. Kakkar AK, Brenner B et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632):31–39PubMedCrossRefGoogle Scholar
  60. Karthikeyan G, Eikelboom JW et al (2009) Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol 146:142–149PubMedCrossRefGoogle Scholar
  61. Kearon C, O’Donnell M (2011) Graduated compression stockings to prevent venous thromboembolism in hospital: evidence from patients with acute stroke. Pol Arch Intern Med 121(1–2):40–43Google Scholar
  62. Keegan SP, Patrick DM et al (2009) Prevention of perioperative venous thromboembolism. Int Anesthesiol Clin 47(4):55–64PubMedCrossRefGoogle Scholar
  63. Khorana AA, Kuderer NM et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907PubMedCrossRefGoogle Scholar
  64. Kushner FG, Hand M et al (2009) 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54(23):2205–2241Google Scholar
  65. Lachiewicz PF (2009) Comparison of ACCP and AAOS guidelines for VTE prophylaxis after total hip and total knee arthroplasty. Orthopedics 32:74–78PubMedCrossRefGoogle Scholar
  66. Lassen MR, Raskob GE et al (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361(6):594–604PubMedCrossRefGoogle Scholar
  67. Lassen MR, Ageno W et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358(26):2776–2786PubMedCrossRefGoogle Scholar
  68. Leiria TLL, Lopes RD et al (2011) Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. J Thromb Thrombolysis 31:514–522PubMedCrossRefGoogle Scholar
  69. Leissinger CA, Blatt PM et al (2008) Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 83(2):137–143PubMedCrossRefGoogle Scholar
  70. Lip GY, Nieuwlaat R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2):263–272PubMedCrossRefGoogle Scholar
  71. Lopes RD, Becker RC et al (2011) Highlights from the III international symposium of thrombosis and anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil. J Thromb Thrombolysis 32(2):242–266PubMedCrossRefGoogle Scholar
  72. Lopes RD, Alexander KP (2009) Antiplatelet therapy in older adults with non–ST-segment elevation acute coronary syndrome: considering risks and benefits. Am J Cardiol 104(5 Suppl):16C–21CPubMedCrossRefGoogle Scholar
  73. Lopes RD, Elliott LE et al (2009) Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J 30(16):2019–2028PubMedCrossRefGoogle Scholar
  74. Lopes RD, Piccini JP et al (2008) Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. J Thromb Thrombolysis 26(3):167–174PubMedCrossRefGoogle Scholar
  75. Lown B (1967) Electrical reversion of cardiac arrhythmias. Br Heart J 29:469–489PubMedCrossRefGoogle Scholar
  76. Mahaffey KW, Wojdyla DM et al, On Behalf of the PLATO Investigators (2011) Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 124:544–554Google Scholar
  77. Matchar DB, Jacobson A et al (2010) Effect of home testing of international normalized ratio on clinical events. N Engl J Med 363(17):1608–1620PubMedCrossRefGoogle Scholar
  78. Mega JL, Close SL et al (2010) Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis. Lancet 376:1312–1319PubMedCrossRefGoogle Scholar
  79. Mega JL, Braunwald E et al (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374(9683):29–38PubMedCrossRefGoogle Scholar
  80. Mehta SR, Boden WE et al (2008) Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation 118(20):2038–2046Google Scholar
  81. Montalescot G, Wiviot SD et al (2009) Prasugrel compared to clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double blind, randomized controlled trial. Lancet 373:723–731PubMedCrossRefGoogle Scholar
  82. Nagarakanti R, Ezekowitz MD et al (2011) Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 123(2):131–136PubMedCrossRefGoogle Scholar
  83. Nagarajan DV, Lewis PS et al (2004) Is addition of antiplatelet therapy to warfarin beneficial to patients with prosthetic heart valves? Interact Cardiovasc Thorac Surg 3:450–455PubMedCrossRefGoogle Scholar
  84. Nijjer SS, Watson G et al (2011) Safety of clopidogrel being continued until the time of coronary artery bypass surgery in acute coronary syndrome: a meta-analysis of 34 studies. Eur Heart J [Epub ahead of print]Google Scholar
  85. O’Connell C, Razavi P et al (2011) Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost 9(2):305–311PubMedCrossRefGoogle Scholar
  86. Oldgren J, Budaj A et al (2011) Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J [Epub ahead of print]Google Scholar
  87. Oldgren J, Alings M et al (2010) Dabigatran versus warfarin in atrial fibrillation patients with low, moderate, and high CHADS2 score: a RE-LY subgroup analysis. J Am Coll Cardiol 55(10A):A1.E2Google Scholar
  88. Palumbo A, Rajkumar SV et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423PubMedCrossRefGoogle Scholar
  89. Patel MR, Mahaffey KW et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891PubMedCrossRefGoogle Scholar
  90. Pisters R, Lane DA et al (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093–1100PubMedCrossRefGoogle Scholar
  91. Price MJ, Berger PB et al, For the GRAVITAS Investigators (2011) Standard-vs. high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105Google Scholar
  92. Price MJ, Endemann S et al (2008) Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29(8):992–1000PubMedCrossRefGoogle Scholar
  93. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M et al (2011) Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 364:1305–1314Google Scholar
  94. Rodgers A, MacMahon S et al (2000) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355:1295–1302CrossRefGoogle Scholar
  95. Rothberg MB, Celestin C et al (2005) Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 143(4):241–250PubMedGoogle Scholar
  96. Santos AT, Kalil RA et al (2006) A randomized, double-blind, and placebo-controlled study with tranexamic acid of bleeding and fibrinolytic activity after primary coronary artery bypass grafting. Braz J Med Biol Res 39(1):63–69PubMedCrossRefGoogle Scholar
  97. Sibbing D, Stegherr J et al (2010) A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol 55(6):558–565PubMedCrossRefGoogle Scholar
  98. Sibbing D, Braun S et al (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53(10):849–856PubMedCrossRefGoogle Scholar
  99. Siller-Matula JM, Jilma B et al (2010) Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 8(12):2624–2641PubMedCrossRefGoogle Scholar
  100. Singer DE, Chang Y et al (2009) The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 151:297–305PubMedGoogle Scholar
  101. Singer DE, Albers GW et al (2008) Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):546S–592SPubMedCrossRefGoogle Scholar
  102. Steg PG, Mehta SR et al (2011) RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 32(20):25–41CrossRefGoogle Scholar
  103. Steg PG, FitzGerald G et al (2009) Risk stratification in non–ST-segment elevation acute coronary syndromes: troponin alone is not enough. Am J Med 122(2):107–108PubMedCrossRefGoogle Scholar
  104. Subherwal S, Bach RG et al (2009) Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 119(14):1873–1882PubMedCrossRefGoogle Scholar
  105. Thygesen K, Alpert JS et al (2007) Universal definition of myocardial infarction. J Am Coll Cardiol 50(22):2173–2195PubMedCrossRefGoogle Scholar
  106. van Giezen JJ, Sidaway J et al (2011) Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther [Epub ahead of print]Google Scholar
  107. Waldo AL, Becker RC et al, NABOR Steering Committee (2005) Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 46(9):1729–1736Google Scholar
  108. Wallentin L, Yusuf S et al (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376(9745):975–983PubMedCrossRefGoogle Scholar
  109. Wallentin L (2009) P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 30(16):1964–1977PubMedCrossRefGoogle Scholar
  110. Wallentin L, Becker RC et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045–1057PubMedCrossRefGoogle Scholar
  111. Wann LS, Curtis AB et al (2011) 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 57(11):1330–1337Google Scholar
  112. Wann LS, Curtis AB et al (2011) 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline). J Am Coll Cardiol 57:223–242PubMedCrossRefGoogle Scholar
  113. Wiviott SD, Braunwald E et al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118(16):1626–1636Google Scholar
  114. Wiviott SD, Braunwald E et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001–2015PubMedCrossRefGoogle Scholar
  115. Wright RS, Anderson JL et al (2011) 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123:2022–2060Google Scholar
  116. Yang X, Alexander KP et al (2005) The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 46(8):1490–1495PubMedCrossRefGoogle Scholar
  117. Yusuf S, Mehta SR et al (2006a) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354(14):1464–1476PubMedCrossRefGoogle Scholar
  118. Yusuf S, Mehta SR et al (2006b) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295(13):1519–1530PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Renato D. Lopes
    • 1
    • 2
  • Richard C. Becker
    • 1
  • L. Kristin Newby
    • 1
  • Eric D. Peterson
    • 1
  • Elaine M. Hylek
    • 3
  • Christopher B. Granger
    • 1
  • Mark Crowther
    • 4
  • Tracy Wang
    • 1
  • Antonio C. Carvalho
    • 2
  • Otavio Berwanger
    • 5
  • Roberto R. Giraldez
    • 6
  • Gilson Soares Feitosa
    • 7
  • Jorge Pinto Ribeiro
    • 8
  • Eduardo Darze
    • 9
  • Renato A. K. Kalil
    • 10
  • Marianna Andrande
    • 11
  • Fabio Villas Boas
    • 12
  • Jadelson Andrade
    • 13
  • Ana Thereza Rocha
    • 14
  • Robert A. Harrington
    • 1
  • Antonio C. Lopes
    • 2
  • David A. Garcia
    • 15
  1. 1.Duke Clinical Research InstituteDuke University Medical CenterDurhamUSA
  2. 2.Federal University of São Paulo, Paulista School of MedicineSão PauloBrazil
  3. 3.Boston UniversityBostonUSA
  4. 4.McMaster UniversityHamiltonCanada
  5. 5.Research Institute HCORHeart HospitalSão PauloBrazil
  6. 6.São Paulo University Medical SchoolSão PauloBrazil
  7. 7.Bahiana School of Medicine and Public HealthSalvadorBrazil
  8. 8.Federal University of Rio Grande do SulPorto AlegreBrazil
  9. 9.Cardio-Pulmonar InstituteSalvadorBrazil
  10. 10.Federal University of Health Science of Porto AlegrePorto AlegreBrazil
  11. 11.Sirio Libanes HospitalSão PauloBrazil
  12. 12.Spanish Hospital, Research CenterSalvadorBrazil
  13. 13.Bahia HospitalSalvadorBrazil
  14. 14.Federal University of BahiaSalvadorBrazil
  15. 15.University of New Mexico Health Sciences CenterAlbuquerqueUSA

Personalised recommendations